Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at the effects of surgery, radiation therapy, chemotherapy, and hormone therapy on biomarkers in women with stage I, stage II, stage III breast cancer, or ductal carcinoma in situ that can be removed by surgery.
| Condition | Intervention |
|---|---|
|
Breast Cancer |
Drug: chemotherapy Drug: endocrine therapy Genetic: DNA methylation analysis Genetic: protein analysis Other: laboratory biomarker analysis Other: questionnaire administration Procedure: adjuvant therapy Procedure: conventional surgery Radiation: radiation therapy |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer |
- Change in high-sensitivity C-reactive protein and gene methylation over time [ Time Frame: indefinite ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Serum
| Estimated Enrollment: | 30 |
| Study Start Date: | May 2006 |
-
Drug: chemotherapy
OBJECTIVES:
- Measure the effects of surgery and radiation on concentrations of high-sensitivity C-reactive protein (hsCRP) in women with newly diagnosed stage I-III invasive breast cancer or ductal carcinoma in situ.
- Measure the effects of chemotherapy and/or endocrine therapy on concentrations of hsCRP in these patients.
- Summarize the differences in preoperative to peri-chemotherapy hsCRP concentrations separately for patients who do and who do not receive growth factors during chemotherapy.
- Observe the change in hsCRP concentrations and gene methylation over time with local and systemic treatment in these patients.
- Explore prevalence of baseline and change in methylation in a panel of genes that is known to be frequently and specifically hypermethylated in breast cancer.
OUTLINE: This is a prospective study.
A blood sample is collected at baseline, approximately 1 week after surgery, and at the time of a routine follow-up visit 3-6 months after completion of all local and systemic therapy, except for patients receiving endocrine therapy. For patients receiving adjuvant chemotherapy, a blood sample is collected prior to beginning chemotherapy and once during the final 2 courses of chemotherapy. For patients receiving radiotherapy, a blood sample is collected during the final 2 weeks of radiotherapy. For patients receiving endocrine therapy, a blood sample is collected between 2 and 6 months after starting endocrine therapy. Patients also complete a questionnaire about overall health and concurrent medications at baseline and during each follow-up visit.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with newly diagnosed ductal carcinoma in situ or invastive breast cancer.
DISEASE CHARACTERISTICS:
Histologically and/or cytologically confirmed stage I-III invasive breast carcinoma or ductal carcinoma in situ
- Newly diagnosed disease
Patient must be initiating a new course of treatment for breast carcinoma, including surgery (mastectomy or lumpectomy with or without nodal evaluation) with or without any of the following:
- Radiation therapy
- Chemotherapy
- Endocrine therapy
- No known or suspected metastatic disease
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- No infectious or inflammatory condition, at the discretion of the principal investigator
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer
PRIOR CONCURRENT THERAPY:
More than 6 months since prior surgery
- Fine-needle aspirate or biopsy allowed
- More than 6 months since prior radiotherapy
- More than 6 months since prior chemotherapy
- More than 6 months since prior endocrine therapy
- No neoadjuvant endocrine therapy or chemotherapy
More than 2 weeks since prior and no concurrent regular use of any of the following:
- Hydroxymethyl glutaryl coenzyme A reductase inhibitor (statin)
- Nonsteroidal anti-inflammatory drug (NSAID)*
- Cyclooxygenase-2 (COX-2) inhibitor
- Aspirin*
- Acetaminophen and opioid use is permitted as needed NOTE: *Use of these products ≤ 2 times per week at standard over-the-counter doses allowed
Contacts and Locations| United States, Maryland | |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Baltimore, Maryland, United States, 21231-2410 | |
| Principal Investigator: | Vered Stearns, MD | Sidney Kimmel Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Sidney Kimmel Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00373191 History of Changes |
| Other Study ID Numbers: | J0575 CDR0000485360, P30CA006973, JHOC-J0575, JHOC-SKCCC-J0575 |
| Study First Received: | September 6, 2006 |
| Last Updated: | October 2, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
|
stage I breast cancer stage II breast cancer stage IIIA breast cancer |
stage IIIB breast cancer stage IIIC breast cancer ductal breast carcinoma in situ |
Additional relevant MeSH terms:
|
Breast Neoplasms Carcinoma in Situ Carcinoma, Intraductal, Noninfiltrating Neoplasms by Site Neoplasms Breast Diseases |
Skin Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Adenocarcinoma Neoplasms, Ductal, Lobular, and Medullary |
ClinicalTrials.gov processed this record on June 18, 2013